Adverse drug reactions (ADRs) are a significant cause of hospital admissions and treatment discontinuation worldwide. Conventional approaches often fail to detect rare or delayed effects of ...

October 1, 2008 (Vol. 28, No. 17) Pharmacogenomics Is Increasingly Being Employed to Improve Drug Safety Profiles It is common knowledge that genetic influences are often significant in predicting ...

“Most approaches to preventing adverse drug events in older people have focused on getting doctors to prescribe the right drug in the first place,” said Steinman. “But, it turns out that the majority ...

In a recent study published in Therapies, researchers presented an overview of sex-based differences in adverse drug reactions (ADRs) based on epidemiology, technique, and underlying mechanism ...

Not surprisingly, since 1985 there has been a dramatic rise in the number of newly approved drugs by the US FDA that contain pharmacogenomic information. [11, 102] So far, of the product labels ...

For example, it estimated a 94.06% probability of hepatotoxicity for erythromycin, 88.44% for nephrotoxicity and 75.8% for hypertension in cisplatin.

Pharmacogenomic Biomarkers of Susceptibility to Adverse Drug Reactions: Just Around the Corner or Pie in the Sky? Mark I. Avigan Disclosures Personalized Medicine. 2009;6 (1):67-78. 0 ...

For example, it estimated a 94.06% probability of hepatotoxicity for erythromycin, 88.44% for nephrotoxicity and 75.8% for hypertension in cisplatin.